The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs
Timeframe: Up to approximately 60 days
Part 1A, Part 1B , Part 1C: Dose discontinued due to AE
Timeframe: Up to 30 days
Part 2A, Part 2B: Incidence of AEs and SAEs
Timeframe: Up to 5 months
Part 2A, Part 2B: Dose interruptions and reductions
Timeframe: Up to 4 months
Part 2A, Part 2B: Dose intensity
Timeframe: Up to 4 months
Part 2B: Fetal hemoglobin (HbF)%
Timeframe: Month 4